Daniel Castaneda

Daniel Castaneda

Auto-generated profile, based on publicly available information

Daniel Castaneda

Digestive Disease Institute, Cleveland Clinic Florida, Weston, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DCDaniel Castaneda
Daniel Castaneda
AGAdalberto Jose Gonzalez
Adalberto Jose Gonzalez
MAMohammad Alomari
Mohammad Alomari
KTKanwarpreet Tandon
Kanwarpreet Tandon
XZXaralambos Bobby Zervos
Xaralambos Bobby Zervos
From hepatitis A to E: A critical review of viral hepatitis

1 July 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SSShailja Shah
Shailja Shah
JHJoren R. Ten Hove
Joren R. Ten Hove
DCDaniel Castaneda
Daniel Castaneda
CPCarolina Palmela
Carolina Palmela
EMErik Mooiweer
Erik Mooiweer
JTJoana Torres
Joana Torres

1 April 2019 in Gastroenterology
Verified
Journal Article
Open access
PDF file
RMRemi Mahmoud
Remi Mahmoud
SSShailja C. Shah
Shailja C. Shah
JHJoren R. Ten Hove
Joren R. Ten Hove
JTJoana Torres
Joana Torres
EMErik Mooiweer
Erik Mooiweer
SISteven H. Itzkowitz
Steven H. Itzkowitz
Background & Aims Patients with inflammatory bowel diseases who have postinflammatory polyps (PIPs) have an increased risk of colorectal neoplasia (CRN). European guidelines propose that patients with PIPs receive more frequent surveillance colonoscopies, despite limited evidence of this increased risk. We aimed to define the risk of CRN and colectomy in patients with inflammatory bowel diseases and PIPs. Methods We conducted a multicenter retrospective cohort study of patients with inflammatory bowel diseases who underwent colonoscopic surveillance for CRN, from January 1997 through January 2017, at 5 academic hospitals and 2 large nonacademic hospitals in New York or the Netherlands. Eligible patients had confirmed colonic disease with duration of at least 8 years (or any duration, if they also had primary sclerosing cholangitis) and no history of advanced CRN (high-grade dysplasia or colorectal cancer) or colectomy. The primary outcome was occurrence of advanced CRN according to PIP status; secondary outcomes were occurrence of CRN (inclusive of low-grade dysplasia) and colectomy. Results Of 1582 eligible patients, 462 (29.2%) had PIPs. PIPs were associated with more severe inflammation (adjusted odds ratio 1.32; 95% confidence interval [CI] 1.13–1.55), greater disease extent (adjusted odds ratio 1.92; 95% CI 1.34–2.74), and lower likelihood of primary sclerosing cholangitis (adjusted odds ratio 0.38; 95% CI 0.26–0.55). During a median follow-up period of 4.8 years, the time until development of advanced CRN did not differ significantly between patients with and those without PIPs. PIPs did not independently increase the risk of advanced CRN (adjusted hazard ratio 1.17; 95% CI 0.59–2.31). The colectomy rate was significantly higher in patients with PIPs (P = .01). Conclusions In a retrospective analysis of data from 2 large independent surveillance cohorts, PIPs were associated with greater severity and extent of colon inflammation and higher rates of colectomy, but were not associated with development of any degree of CRN. Therefore, intervals for surveillance should not be shortened based solely on the presence of PIPs.

1 August 2018 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
DCDaniel Castaneda
Daniel Castaneda
VPVioleta B. Popov
Violeta B. Popov
EVElijah Verheyen
Elijah Verheyen
PWPraneet Wander
Praneet Wander
SGSeth A. Gross
Seth A. Gross

22 August 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
RMRemi Mahmoud
Remi Mahmoud
SSShailja C. Shah
Shailja C. Shah
JTJoana Torres
Joana Torres
DCDaniel Castaneda
Daniel Castaneda
JGJason Glass
Jason Glass
SISteven H. Itzkowitz
Steven H. Itzkowitz
Little is known about the clinical significance of indefinite dysplasia (IND) in patients with inflammatory bowel diseases (IBD) undergoing colonoscopic surveillance for colorectal neoplasia. We conducted a retrospective cohort analysis of 492 patients with colonic IBD for 8 or more years or concomitant primary sclerosing cholangitis, with no history of advanced colorectal neoplasia (high-grade dysplasia or colorectal cancer) or colectomy, undergoing colorectal neoplasia surveillance at a tertiary IBD referral center from 2001 through 2017. Subjects received consistent histopathologic grading of dysplasia. We collected data on time to development of (advanced) colorectal neoplasia or colectomy using Kaplan Meier methods. We identified factors independently associated with (advanced) colorectal neoplasia with multivariable Cox regression analysis. After 2149 person-years of follow-up, 53 patients (10.8%) received a diagnosis of IND without prior or synchronous low-grade dysplasia (LGD). Compared to patients without dysplasia, patients with IND had a significantly higher risk of advanced colorectal neoplasia (adjusted hazard ratio, 6.85; 95% CI, 1.78-26.4) and colorectal neoplasia (adjusted hazard ratio, 3.25; 95% CI, 1.50-7.05), but not colectomy (P = .78). Compared to IND, LGD was associated with a significantly higher risk of advanced colorectal neoplasia (P = .05). Following a diagnosis of no dysplasia, IND only, or LGD, the incidence rates of advanced colorectal neoplasia were 0.4% per patient-year, 3.1% per patient-year, and 8.4% per patient-year, respectively. In a retrospective analysis of patients with IBD undergoing colorectal neoplasia surveillance with consistent histopathologic grading of dysplasia, IND was independently associated with a significant increase in risk of advanced colorectal neoplasia. These findings require validation and if confirmed, a reappraisal of the colorectal neoplasia surveillance guidelines.

18 August 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LMLeyla Maric
Leyla Maric
DCDaniel Castaneda
Daniel Castaneda
HSHarjinder Singh
Harjinder Singh
PBPablo Bejarano
Pablo Bejarano
BCBrenda Jimenez Cantisano
Brenda Jimenez Cantisano
FCFernando J. Castro
Fernando J. Castro